



## Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294  
E-mail : info@indswiflabs.com Website : www.indswiflabs.com  
CIN No. L24232CH1995PLC015553



Ref.: ISLL:CH:2022:

Date: 23<sup>rd</sup> June, 2022

The President,  
Corporate Relationship Department,  
Bombay Stock Exchange Limited,  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai 400 001

The Vice President,  
National Stock Exchange of India Limited,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/2, G-Block,  
Bandra Kurla Complex, Bandra (E),  
Mumbai 400 051

BSE Scrip Code: 532305

NSE Symbol: INDSWFTLAB

Sub: Intimation of Investment in a Joint Venture

Ref.: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Company has entered into a Joint Venture, which shall be operated through a newly incorporated entity viz MJM Remedies Private Limited, where the Company shall have 75% stake and rest 25% stake shall be held by Mr. Ramesh Mehta. The new joint venture will explore the opportunities in the pharmaceutical field.

The disclosures under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is enclosed as Annexure I to this intimation.

We request you to take the same on record.

Thanking you,

For IND-SWIFT LABORATORIES LTD.

PARDEEP VERMA  
AVP-CORPORATE AFFAIRS &  
COMPANY SECRETARY



Encl: As Above



# Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
 Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294  
 E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
 CIN No. L24232CH1995PLC015553



## Annexure-I

**Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015.**

Sr. No.	Details of Events that need to be provided	Information of such events (s)
1.	Name of the Target entity details in brief such as size, turnover etc.	MJM REMEDIES PRIVATE LIMITED  Turnover, Size: Not Applicable since it is a newly incorporated company.
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?  If yes, nature of interest and details thereof and whether the same is done at "arms length";	The investment will not fall into a related party transaction.  Ind-Swift Laboratories Limited (ISLL) will be holding 75% Stake in the Joint Venture entity.
3.	Industry to which Target entity being acquired belongs	The Target entity belongs to Pharmaceutical Industry.
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	To explore business opportunities available in the Pharma space other than the pharma segment in which ISLL is already present.
5.	Brief details of any governmental or regulatory approvals required for the acquisition.	Normal Regulatory Approvals as are required to run a pharma business shall be obtained in due course.
6	Indicative time period for completion	The Investment will be an on-going investment to be undertaken from time to time as per the need of the Joint Venture.
7	Nature of consideration - Whether Cash consideration or share swap and details of the same	Cash consideration
8	Percentage of shareholding/ control acquired and/ or number of shares acquired	ISLL shall hold 75% stake in the Company.
9	Cost of acquisition or the price at which the shares are acquired	Initially the Board has approved an investment of upto 50 Lacs, which will be invested over a period of time.





# Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294  
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
CIN No. L24232CH1995PLC015553



10	Brief Background about entity acquired in terms of Products/line of business acquired, Date of incorporation, History of last 3 years Consolidated turnover (Rs. in lakhs), Country in which the acquired entity has presence and any other significant information (in brief)	<p>ISLL shall have 75 % stake in the newly incorporated entity, incorporated w.e.f. 22.06.2022.</p> <p>Turnover: Not Applicable since it is a newly incorporated company</p> <p>Product Line of Business - MJM Remedies Private Limited shall have presence in the Pharmaceutical Industry.</p> <p>Country in which the entity has presence - India.</p>
----	--	--

